Best Genomics Companies in Maryland, United States
The 87 best Genomics companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Delfi Diagnostics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Delfi Diagnostics Provider of DNA sequencing for cancer detection 67Funding top 17%Patents top 24%AI top 28%Moat top 28% All 11 signals ▾Fundingtop 17% Patentstop 24% AItop 28% Moattop 28% Innovationtop 32% Talenttop 42% Growthtop 48% Marketbottom 49% Techbottom 47% Globalbottom 36% Newsbottom 33% Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $332M | 6 mo ago | 197 | 2019 | Victor Velculescu Founder and Board of Directors | WordPressApple iCloud MailMySQL+16 | 52 patents Non‑invasive cancer detection and monitoring via cfDNA fragmentation and methylation profiling | 1 job opening · 1 partnership · 3 awards |
| 2 | Sirnaomics Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease 80Patents top 14%Funding top 15%Innovation top 17%Growth top 28% All 9 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Growthtop 28% Moattop 35% Markettop 46% Talentbottom 49% Globalbottom 48% Newsbottom 21% Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $267M | 9 mo ago | 88 | 2007 | Patrick Lu President and CEO | — | 276 patents siRNA therapeutics and nanoparticle delivery systems for targeted gene silencing | 1 launch |
| 3 | Personal Genome Provider of advanced technology solutions for cancer genome analysis | $252M | 64 mo ago | 109 | 2010 | — | Craft CMSPHPYii+14 | 143 patents Patents concentrated in chemistry & materials | — |
| 4 | VIRxSYS Developing genetic therapies for HIV and cancer | $106M | 174 mo ago | — | 1998 | Riku Heikki Rautsola Ex President and CEO | — | 105 patents Therapeutic apoptosis-inducing agents, lentiviral gene‑therapy vectors, and RNA trans‑splicing platforms | — |
| 5 | OpGen Developer of diagnostics and bioinformatics platforms for providers | $78M | 63 mo ago | 100 | 2002 | — | WordPressMySQLPHP+16 | 111 patents Antimicrobial resistance profiling and rapid antibiotic susceptibility testing technologies. | — |
| 6 | OriGene Provider and manufacturer of proteins, antibodies, and other molecular tools for research applications | $70M | 132 mo ago | 141 141 → 130 (-8%) | 1996 | — | Cart FunctionalityMagentoMySQL+34 | 9 patents Protein microarray platforms for biomarker discovery, disease diagnostics, and gene expression profiling | 1 launch |
| 7 | Haystack Oncology Provider of personalized cancer diagnostic tests | $67M | 44 mo ago | 45 | 2021 | — | — | — | — |
| 8 | Genvec Developer of gene-based vaccines for hearing loss and balance disorders | $62M | 158 mo ago | 16 | 1992 | — | — | 331 patents Adenoviral vector platforms for veterinary and human vaccines and gene therapy | — |
| 9 | RoosterBio Developer of human mesenchymal stem cells and extracellular vesicles | $40M | 27 mo ago | 69 69 → 58 (-16%) | 2012 | Jon Rowley Founder & Chief Product Officer | Cart FunctionalityWooCommerceWordPress+27 | 23 patents Optimizing stem cell culture media and extracellular matrices for biofabrication and printing | 3 launchs |
| 10 | Akonni Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification | $40M | 57 mo ago | 12 12 → 15 (+25%) | 2003 | — | — | — | — |
| 11 | Synthetic Biologics Developing oncolytic virus therapies to overcome solid tumor barriers | $31M | 46 mo ago | 21 | 1986 | — | — | 208 patents Microbiome-protective enzyme therapeutics and engineered biologics for infection and metabolic control | — |
| 12 | Gene Logic Integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray… | $29M | 347 mo ago | 85 | 1994 | — | — | — | — |
| 13 | Scanogen Provider of single-molecule biosensors for cancer diagnostics 29Talent top 28%Moat top 32%Funding top 33%Patents top 35% All 9 signals ▾Talenttop 28% Moattop 32% Fundingtop 33% Patentstop 35% Innovationtop 42% Productbottom 44% Globalbottom 35% Techbottom 28% Marketbottom 21% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $29M | 10 mo ago | 7 | 2011 | — | BootstrapApache HTTP ServerCloudflare+7 | 26 patents Optical detection and imaging systems for biochemical analyte identification | — |
| 14 | Vector BioMed Provider of vector manufacturing solution and commercialization services | $22M | 40 mo ago | — | 2021 | Boro Dropulic CEO | WordPressMySQLPHP+24 | — | 1 launch |
| 15 | Innovative Biosensors Developer of self-contained biosensor system for rapid diagnostic tests | $20M | 171 mo ago | 1 | 2003 | — | — | — | — |
| 16 | Circulomics Provider of a platform for genome profiling and biomarker analysis | $15M | 69 mo ago | 10 | 2009 | — | — | 16 patents Silica‑based magnetic nanomaterials for high‑molecular‑weight DNA extraction and size selection | — |
| 17 | mRNA Developer of therapeutics for the treatment of cancer, rare diseases, and others | $12M | 50 mo ago | 9 | 2016 | Dong Shen CEO | — | — | — |
| 18 | Vigene Biosciences Developer of life science research reagents for drug discovery and functional genomics | $10M | 74 mo ago | 45 | 2012 | Zairen Sun CEO | — | — | — |
| 19 | CosmosID Developer of next-generation sequencing (NGS) technologies for the detection of microorganisms | $7M | 84 mo ago | 7 | 2008 | — | WordPressMySQLPHP+23 | 19 patents Microbial DNA sequencing for identification, quantification, and trait analysis of microorganisms. | — |
| 20 | BioMarker Strategies Develops Cancer Diagnostics System | $7M | 105 mo ago | 8 | 2007 | Jerry Parrott President | — | 31 patents Predictive biomarkers and assays for enhancing immune checkpoint inhibitor cancer therapy | — |
| 21 | DioGenix Next generation sequencing tests for multiple sclerosis. | $5M | 150 mo ago | — | 2004 | — | Microsoft ASP.NETcore-jsSlick+11 | — | — |
| 22 | Creatv Bio Developer of blood based tests for treating cancer | $4M | 81 mo ago | 9 | 2020 | — | — | — | — |
| 23 | Ibex Biosciences Developer of antibody and gene therapy technologies for oncology, inflammation, autoimmune disease and… | $4M | 16 mo ago | 11 | 2015 | — | — | — | — |
| 24 | InforMax Scientific solutions provider: instruments, reagents, software, and services for researchers | $4M | 323 mo ago | 223 | 1990 | Alex Titomirov Founder | — | — | — |
| 25 | MultiplexDX Provider of solutions for the molecular diagnostics market | $3M | 41 mo ago | 35 | 2015 | — | Webflowcore-jsjQuery+11 | — | — |
| 26 | Papgene Diagnostics company focused on commercializing molecular tests for early detection of cancer | $3M | 124 mo ago | — | 2014 | Luis Diaz Founder | — | — | — |
| 27 | Plasmonix Exploring Scrum development, agile methodologies, and project management approaches | $3M | 131 mo ago | — | 2009 | William Gust Founder & Ex-CEO | — | 3 patents Plasmonic-enhanced fluorescence microarray substrates for increased signal detection | — |
| 28 | Ravgen Non-invasive prenatal DNA testing for Down syndrome and single gene disorders | $2M | 55 mo ago | 6 | 2000 | Rav Dhallan Chairman And Ceo | — | 26 patents Rapid genomic variation detection and prenatal chromosomal abnormality testing | — |
| 29 | Silvec Developer of RNA-based genetic breeding solutions for plants | $2M | 12 mo ago | 26 26 → 13 (-50%) | 2019 | Anne Simon Co-Founder | — | — | — |
| 30 | NeoDiagnostix Limited information available | $2M | 207 mo ago | — | 2004 | Richard Pinnola CEO | — | 32 patents Automated image analysis for cervical cytology and cancer cell diagnostics | — |
| 31 | BioDatomics Next-generation bioinformatics tools for accelerated NGS data analysis and collaboration | $1M | 127 mo ago | 11 | 2012 | Alan Taffel Co-Founder & CEO | — | 11 patents Visualization and UI tools for big‑data scientific workflow creation and execution platforms | — |
| 32 | Intelligent Substrates Provider of microenvironments for in vitro cell culture research, tissue engineering, and drug discovery | $980K | 200 mo ago | — | 2007 | Jan Hoh Co-Founder | — | — | — |
| 33 | Polaris Genomics Developer genomic-based diagnostics and therapeutics for neurological conditions | $800K | 10 mo ago | 10 | 2017 | Tshaka Cunningham Co-Founder | — | — | — |
| 34 | xMD Developer of laboratory instruments and consumables for life science research | $775K | 58 mo ago | 2 | 2015 | — | — | 8 patents Microfluidic devices for targeted extraction of biomolecules from tissue samples | — |
| 35 | CCC DirectHit Pharmacodiagnostic test for breast cancer | $745K | 185 mo ago | — | 2004 | John Hughes CEO & President | — | — | — |
| 36 | Full Genomes Consumer facing genome sequencing company | $602K | 87 mo ago | 3 | 2012 | Paul Conroy Founder & Director | — | — | — |
| 37 | NexGen Forensic Sciences Developer of a DNA analysis tools for precision medicine development | $450K | 39 mo ago | — | — | Andrew B Feldman CEO | — | — | — |
| 38 | HepC Developer of antiviral biologic products | $400K | — | — | 2005 | Thomas Bakacs CEO | — | — | — |
| 39 | Gaskiya Developer of protein based diagnosis test for aquatic disease | $325K | 68 mo ago | 4 | 2016 | Mary Larkin Founder & CEO | — | — | — |
| 40 | Nanocrine Provider of a cell analysis and drug design tool for researchers | $300K | 36 mo ago | 4 | 2018 | Jim Bailey Co-Founder | — | — | — |
| 41 | GalaxyWorks Provider of a SaaS-based omics data analysis platform for healthcare providers | $280K | 81 mo ago | 2 | 2019 | Dannon Baker Co-Founder | — | — | — |
| 42 | Rise Therapeutics Developer of targeted immunological-based biologics for gastrointestinal (GI) inflammatory disease | $200K | 13 mo ago | 10 | 2016 | Neil Fanger Co-Founder | — | — | — |
| 43 | Capsulomics Developer of methylation based diagnostic tests for esophageal cancer risk | $200K | 55 mo ago | 13 | 2018 | Daniel Lunz Co-Founder & CEO | — | 4 patents Predictive analytics for Barrett's esophagus progression using genomic/biomarker data | — |
| 44 | Cellomics Technology Provider of products and services to genetically engineer mammalian somatic and stem cells | $150K | 158 mo ago | 4 | 2006 | — | Cart FunctionalityBootstrapMicrosoft ASP.NET+7 | 116 patents Patents concentrated in computing, sensing & instrumentation | — |
| 45 | EdgeBio Manufacturer and distributor for DNA sequencing and purification | $109K | 191 mo ago | 11 | 1989 | — | UbuntuHeadless UITailwind CSS+15 | — | — |
| 46 | Ariadne Diagnostics Developer of diagnostic tests for oncology and neurodegenerative diseases | $100K | 155 mo ago | 5 | 2011 | Ilya Mazo Co-Founder & CEO | — | — | — |
Top 12 Genomics companies in Maryland
#1
Series B · Baltimore, Maryland · founded 2019 · 197 employees$331.6Mraised▾
Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.
- Dec 2025Conventional Debt$34.3M
- Jun 2024Series B—
- Jul 2022Series B$225M
- Jan 2021Series A$101.1M
#2
Public · Gaithersburg, Maryland · founded 2007 · 88 employees$267Mraised▾
Developer of RNA-based therapeutics for the treatment of cancer and fibrosis disease. The company has proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead, to develop drug candidate pipeline which include STP122G for cardiovascular disease treatment. It also, develops pipeline of drugs for cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.
- Sep 2025Post IPO$17.7M
- Jul 2021Series E$105M
- Oct 2020Series D$105M
- Jul 2019Series C$25M
#3
Funding Raised · Baltimore, Maryland · founded 2011 · 7 employees$28.6Mraised▾
Provider of single-molecule biosensors for cancer diagnostics. The company's semiconductor-based technology uses DNA supercoiling to convert nucleic acid hybridization into a mechanical signal for rapid diagnostics. The first application is for the detection of drug-resistant microbes, specifically tuberculosis.
- Jul 2025Grant (prize money)$3M
- Jun 2025Grant (prize money)$5M
- May 2025Grant (prize money)$3.3M
- Aug 2023Grant (prize money)$2M
#4
Funding Raised · Rockville, Maryland · founded 2019 · 26 employees$1.6Mraised▾
Developer of RNA-based genetic breeding solutions for plants. It offers genetic modification in plants to protect them against diseases. It offers solutions for trees, vines, and bushes.
- Jun 2025Grant (prize money)$98K
- Mar 2025Grant (prize money)$256.5K
- Sep 2023Grant (prize money)$650K
- May 2022Grant (prize money)$175K
#5
Series A · Rockville, Maryland · founded 2017 · 10 employees$800Kraised▾
Developer genomic-based diagnostics and therapeutics for neurological conditions. The company uses a proprietary bioinformatics engine TruNorth Platform for Neuropsychiatric genomic analysis. Also, it develops PTS-ID a genomic test for the diagnosis and treatment of Post-traumatic stress disorder.
- Aug 2025Conventional Debt$250K
- Oct 2023Conventional Debt$1M
- May 2023Conventional Debt$1M
- Feb 2021Conventional Debt$100K
#6
Seed · Cumberland, Maryland · founded 2015 · 11 employees$4.2Mraised▾
Developer of antibody and gene therapy technologies for oncology, inflammation, autoimmune disease and retinal disease. The pipeline includes therapeutic antibody programs to treat various inflammatory conditions and oncology, gene therapies for Gaucher's disease and other metabolic storage disorder conditions, and stem cell therapies for retinal regeneration and cardiac muscle regeneration.
- Feb 2025Seed$70K
- Feb 2025Conventional Debt—
- Jan 2020Seed$2.4M
- Sep 2017Grant (prize money)$277.8K
#7
Series B · Frederick, Maryland · founded 2012 · 69 employees$40.2Mraised▾
Developer of human mesenchymal stem cells and extracellular vesicles. The company specializes in human bone marrow-derived and adipose-derived MSCs and associated, highly-engineered media formulations for the expansion of these cells.
- Mar 2024Conventional Debt—
- Mar 2024Series B$12M
- Sep 2019Series B$21.5M
- Oct 2017Grant (prize money)—
#8
Acquired · Baltimore, Maryland · founded 2010 · 109 employees$252.4Mraised▾
Provider of advanced technology solutions for cancer genome analysis. PGDx has developed proprietary techniques that identify mutations found in a patient’s tumor through noninvasive testing of circulating tumor DNA. PGDx is CLIA certified for high-complexity molecular testing using the whole exome, targeted and plasma analysis approaches.
- Feb 2021Series C$103M
- May 2020Series B$2.8M
- Jun 2019Series B$5M
- Oct 2018Series B$42M
#9
Seed · Rockville, Maryland · founded 2016 · 10 employees$200Kraised▾
Developer of targeted immunological-based biologics for gastrointestinal (GI) inflammatory disease. It offers oral delivery platform, TriPartite X (TPX) is a novel DNA assembly approach that allows for the creation of recombinant probiotics to escort targeted protein therapies to the intestinal space. Its drug pipeline includes R-2487, an immunobiotic drug that can cause autoimmunity in tissues distal from the intestinal tract; R-3750 which is being developed for the treatment of gastrointestinal (GI) inflammatory disease.
- May 2025Grant (prize money)$2.9M
- Apr 2025Grant (prize money)$2.1M
- Mar 2025Grant (prize money)$2.1M
- Mar 2025Grant (prize money)$2.9M
#10
Acquired · Baltimore, Maryland · founded 2021 · 45 employees$67Mraised▾
Provider of personalized cancer diagnostic tests. It offers circulating tumor DNA detection technology to optimize minimal residual disease (MRD) testing for recurrent or resistant diseases. It also has a tumor-informed liquid biopsy-based test that begins with tissue-based whole-exome sequencing to identify patient-specific tumor mutations.
- Oct 2022Series A$67M
#11
Public · Rockville, Maryland · founded 2002 · 100 employees$77.5Mraised▾
Developer of diagnostics and bioinformatics platforms for providers. The company’s lead product is the Acuitas MDRO Gene Test. Other products include the Acuitas Lighthouse MDRO Management System and the Acuitas Resistome Test. The company’s products and services are designed to enable the identification of hospital patients who are infected with multi-drug resistant organisms, or MDROs.
- Feb 2021Post IPO$25M
- Dec 2020Post IPO$10M
- Jul 2018Post IPO$285.5K
- Sep 2017Post IPO$110K
#12
Late Stage · Rockville, Maryland · founded 1986 · 21 employees$31.4Mraised▾
Developing oncolytic virus therapies to overcome solid tumor barriers. This clinical-stage immuno-oncology company focuses on developing oncolytic viruses designed to selectively kill tumor cells and overcome the protective barriers surrounding solid tumors. Their developmental therapies aim to enable systemic delivery and enhance current standard-of-care treatments, offering the potential for longer lives for patients with difficult-to-treat cancers. The company's engineered oncolytic viruses offer a powerful approach to treating therapeutically challenging cancers, overcoming the limitations of traditional oncolytic viruses. They are exploring technologies to expand their therapeutic approach and combine their viruses with a variety of cancer therapies. The company seeks to transform the cancer therapy landscape through innovative solutions in the biotechnology and pharmaceutical industries.
- Jul 2022Post IPO$3M
- Sep 2017Post IPO$12M
- Sep 2013Grant (prize money)$5.6M
- Nov 2012Post IPO$10.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Maryland is moving
A read on the academic research around Bioinformatics in Maryland — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 136 papers.
- University of Maryland, Baltimore74
- University of Maryland, College Park50
- University of Maryland, Baltimore County9
- Virginia–Maryland College of Veterinary Medicine4
- University of Maryland Extension2
- Genome3→9
- Gene2→5
- Transcriptome3
- Disease3
- Genome3
- Computational biology2
- Encoding (memory)2
- Disease5
- Gene3
- Gene duplication2
- Pathogenesis2
- Folliculin2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.